CytomX Therapeutics CTMX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$18.25M-178% | -$26.51M-240% | -$14.23M-348% | -$154K+97.6% | $23.53M+70.6% | ||
| $4.71M+134% | $1.48M-21.5% | $1.38M-30.6% | $1.43M-24.0% | $2.01M+5.3% | ||
| -$1.37M-19.2% | —— | -$240K— | -$87K+99.2% | -$1.15M-112% | ||
| $67K+108% | $655K+351% | $419K— | -$49K+96.6% | -$804K-238% | ||
| $887K-26.2% | $874K— | —— | —— | $1.2M+199% | ||
| -$9.61M+78.5% | $0+100% | -$4.38M+85.8% | -$17.15M+25.1% | -$44.62M-54.2% | ||
| $37K+2.8% | $37K0.0% | $36K0.0% | $37K0.0% | $36K0.0% | ||
| -$25.55M-21.4% | -$23.24M-16.8% | -$15.55M+25.0% | -$15.75M+19.4% | -$21.04M+19.2% | ||
| $0-100% | $201K+151% | —— | $27K-71.9% | $119K+3.5% | ||
| $242.78M+1,127% | $44.22M-11.2% | $19.69M+59.9% | $108.83M+16.5% | $19.79M— | ||
| $50M-1.0% | $30M-53.8% | $20M-34.4% | $32.5M-71.7% | $50.5M+12.2% | ||
| -$192.78M-730% | -$14.42M-195% | $0-100% | -$76.36M-455% | $30.6M-31.8% | ||
| $228.35M— | $16.26M+687% | $0— | $93.4M+1,900% | $0-100% | ||
| $234.49M— | $16.64M+640% | $253K— | $93.55M+1,735% | $0-100% | ||
| $16.16M+69.2% | -$21.02M— | -$14.86M— | $1.44M-79.7% | $9.55M-49.8% | ||
| $726K+59.9% | $719K-8.6% | $636K-47.9% | $397K-72.4% | $454K-75.7% | ||
| $37K+2.8% | $37K0.0% | $36K0.0% | $37K0.0% | $36K0.0% | ||
| $214K-38.7% | $473K+25.8% | $98K-75.1% | $310K-26.5% | $349K-19.0% | ||
| —— | -$100.5K-279% | -$100.5K-279% | -$100.5K-279% | -$100.5K-279% | ||
| -$3.6M-70.9% | —— | -$326K— | -$1.1M+34.1% | -$2.11M+52.5% | ||
| $887K-26.2% | $874K— | —— | —— | $1.2M+199% | ||
| -$1.13M-4.7% | -$1.16M-9.8% | -$1.13M-9.8% | -$1.11M-9.8% | -$1.08M-9.6% | ||
| $242.78M+1,127% | $44.22M-11.2% | $19.69M+59.9% | $108.83M+16.5% | $19.79M— | ||
| $50M-1.0% | $30M-53.8% | $20M-34.4% | $32.5M-71.7% | $50.5M+12.2% | ||
| $281K— | $381K+108% | $253K— | $177K-30.9% | $0-100% | ||
| $780K— | —— | —— | —— | $0— | ||
| -$9.61M+78.5% | $0+100% | -$4.38M+85.8% | -$17.15M+25.1% | -$44.62M-54.2% | ||
| —— | $750.5K— | $750.5K— | $750.5K— | $750.5K— | ||
| $5.86M— | —— | —— | —— | $0— | ||
| -$25.55M-20.7% | -$23.44M-17.3% | -$15.42M+25.7% | -$15.78M+19.7% | -$21.16M+19.1% | ||
| -$25.55M-20.7% | -$23.44M-17.3% | -$15.42M+25.7% | -$15.78M+19.7% | -$21.16M+19.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does CytomX Therapeutics generate?
- CytomX Therapeutics (CTMX) generated -$80.1M in operating cash flow over the trailing twelve months.
- What is CytomX Therapeutics's free cash flow?
- After $347.0K of capital expenditures, CytomX Therapeutics's free cash flow was -$80.2M over the trailing twelve months, up 1.7% year over year.
- Where does CytomX Therapeutics's cash flow data come from?
- Every line is extracted from CytomX Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
